Comparing the current results to its competitors, Alimera Sciences Inc reported Revenue increase in the 2 quarter 2024 by 52.92 % year on year. The sales growth was above Alimera Sciences Inc's competitors' average revenue growth of 10.59 %, achieved in the same quarter.
Alimera Sciences Inc, slower than the average decrease reported by the company's competitors of -55.45 %. recorded a net loss and most of the company's competitors saw a decline in earnings by -55.45 %
Alimera Sciences Inc's Comment on Competition and Industry Peers
The company’s products ILUVIEN and YUTIQ face competition from major pharmaceutical, specialty pharmaceutical, and biotechnology companies globally. These products compete with anti-VEGF therapies, short-duration corticosteroids, systemic steroids, laser photocoagulation, and other treatments for diabetic macular edema (DME) and non-infectious uveitis affecting the posterior segment (NIU-PS). For DME, specific competitors include Eylea (aflibercept) 4 mg and Eylea HD (aflibercept) 8 mg, marketed by Regeneron in the U.S. and Bayer in the European Economic Area, as well as Vabysmo (faricimab-svoa), marketed by Genentech. Laser photocoagulation and other laser or surgical treatments also compete with ILUVIEN. For NIU-PS, Ozurdex (dexamethasone intravitreal implant), marketed by Allergan, an AbbVie company, is a competitor. These competing therapies may exert pricing pressure on ILUVIEN and YUTIQ.
Mira Pharmaceuticals Inc's business model is focused on the development and sale of pharmaceutical products, with a particular emphasis on research and innovation in the healthcare industry.
Phio Pharmaceuticals Corp's business model revolves around developing and commercializing innovative RNA-based therapeutics to treat various diseases and improve patient outcomes.
Precigen Inc is a biotechnology company that focuses on the development and commercialization of innovative genetic therapies. Their business model revolves around leveraging their proprietary technologies and expertise in gene editing and synthetic biology to create transformative medical solutions. With a strong emphasis on research and development, Precigen aims to bring cutting-edge genetic therapies to market and address critical unmet medical needs.
Sources:
Alimera Sciences Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Alimera Sciences Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
